I am a Professor of Medicine at Dana-Farber Cancer Institute of Harvard Medical School and an internationally recognized leader in the breast cancer field.

Research in my laboratory is dedicated to the molecular analysis of human breast cancer, with the goal of identifying differences between normal and cancerous breast tissue, and using this information to improve the clinical management of patients. We have devoted much effort to developing new ways to study tumors as a whole and have been at the forefront of efforts to analyze purified cell populations from normal and neoplastic human breast tissue at genomic scale and at the level of the single cell. We apply mathematical and ecological models to explore the evolution of breast tumors. We have also had some success in the clinical translation of our findings, notably in the clinical trials of JAK and BET bromodomain inhibitors for the treatment of triple negative breast cancer.

I have received numerous awards for my work, including the Paul Marks Prize for Cancer Research in 2011 and the 2012 AACR Outstanding Investigator Award for Breast Cancer Research.